Molecular cytogenetics encompasses different aspects of chromosome biology. The techniques and procedures to conduct molecular cytogenetics are often used in the areas of medicine and biology. Molecular cytogenetics can help study the structural and functional organization of the nucleus and the chromosome of the cell, expression, and evolution of genes, genome variation in tumor genetics, and medical genetics. The common techniques involved in molecular cytogenetics include fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and array comparative genomic hybridization (aCGH). These techniques can be used in studying cytogenetics of pre and post-natal samples and in cytogenetic testing for cancer.

Market Scope and Structure Analysis

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19.

With COVID-19 spreading all across the world, hospitalization rates declined dramatically. There were several reports of many hospitals operating at less than 50% capacity to curtail noncritical medical services and elective surgeries. Hospitals are even less likely to conduct molecular cytogenetics tests. Therefore, COVID 19 is expected to have a significant impact on the molecular cytogenetics market.

Top Impacting Factors

Increasing cases of cancer and related mortality growth in recent years have significantly helped expand the molecular cytogenetic market. The continued prevalence of cancer has increased the demand for advanced technologies that help understand cancer at a genomic level.

Growing pharmacogenomics activities have positively influenced the market, as many cytogenetic tools have been used over the years for pharmacogenomics biomarker studies.

Growing genetic abnormalities in many people since birth and increasing focus of healthcare systems of many countries on preventive measures for many genetic defects are some of the factors that helped augment the growth of the molecular cytogenetic market in recent years.

However, the implementation of molecular cytogenetic tools and equipment in research and clinical laboratories require high capital investments, which acts as an impeding factor of the molecular cytogenetic market.

Key Market Trends

Research & clinical laboratories segment dominated the molecular cytogenetic market in 2019, due to increasing use of cytogenetic techniques being in clinical diagnosis. Ongoing research pertaining to underlying chromosomal diseases has further enabled this segment to attain a high share in the market.

The implementation of molecular cytogenetics in biotechnology and pharmaceutical companies is expected to grow due to growing demand for targeted therapies.

North America dominates the molecular cytogenetic market, owing to high incidences of cancer and genetic disorders, high healthcare expenditure on reimbursements of health insurance, and increase in the geriatric population.

In 2016, HEALTH BioMed and Thermo Fisher Scientific, Inc. collaborated to support the development of molecular diagnostic kits from HBM. These kits are meant for pharmacogenomics screening and detection of infectious diseases.

IN 2016, Affymetrix was acquired by Thermo Fisher Scientific, Inc., which strengthened Thermo Fisher Scientific's position in the bioscience business and create new opportunities in the market for genetic analysis.

Key Segments Covered

Key Benefits of the Report

• This study presents the analytical depiction of the molecular cytogenetics industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
• The current market is quantitatively analyzed from 2020 to 2030 to highlight the growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
• The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Molecular Cytogenetics Report

• Which are the leading players active in the molecular cytogenetics market?
• How is each segment of the market expected to grow during the forecast period?
• What are the adoption trends for the molecular cytogenetics market in emerging economies and established economies across the world?
• What are the current trends that will influence the market in the next few years?
• What are the driving factors, restraints, and opportunities of the market?
• What future projections would help in taking further strategic steps in the market?
• What are the impacts of COVID-19 on the industry?
• What is molecular cytogenetics?
• What are the current and predicted trends of the market?